These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27883282)

  • 1. Obesity Week 2016 Annual Meeting.
    Marathe PH; Dove AE; Gao HX; Odeh SA; Close KL
    J Diabetes; 2017 Mar; 9(3):215-218. PubMed ID: 27883282
    [No Abstract]   [Full Text] [Related]  

  • 2. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
    Cusi K
    Curr Opin Lipidol; 2016 Dec; 27(6):633-635. PubMed ID: 27805974
    [No Abstract]   [Full Text] [Related]  

  • 5. Obesity in 2015: Advances in managing obesity.
    Dixon JB
    Nat Rev Endocrinol; 2016 Feb; 12(2):65-6. PubMed ID: 26729038
    [No Abstract]   [Full Text] [Related]  

  • 6. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
    Thompson J; Schacht S; Rothenberg F
    Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
    Lingvay I; Leiter LA
    Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
    Scheen AJ
    Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453
    [No Abstract]   [Full Text] [Related]  

  • 12. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
    Rossello X; Yellon DM
    Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research digest.
    Sattar N; Preiss D
    Lancet Diabetes Endocrinol; 2016 Aug; 4(8):651. PubMed ID: 27401823
    [No Abstract]   [Full Text] [Related]  

  • 14. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 15. After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
    Schatz H
    Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):459-460. PubMed ID: 27701709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The cardiovascular outcome is critical].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(3):68. PubMed ID: 27119710
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycemic control and the heart: it matters how you get there.
    Bloomgarden Z
    J Diabetes; 2016 Jul; 8(4):453-4. PubMed ID: 26990043
    [No Abstract]   [Full Text] [Related]  

  • 18. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding EMPA-REG OUTCOME.
    Gilbert RE; Connelly KA
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):930-1. PubMed ID: 26590681
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding EMPA-REG OUTCOME.
    Ceriello A; Genovese S; Mannucci E; Gronda E
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):929-30. PubMed ID: 26590680
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.